Zobrazeno 1 - 10
of 451
pro vyhledávání: '"van Goethem, F."'
Autor:
Eichenbaum, G., Zhou, J., De Smedt, A., De Jonghe, S., Looszova, A., Arien, T., Van Goethem, F., Vervoort, I., Shukla, U., Lammens, L.
Publikováno v:
In Journal of Pharmacological and Toxicological Methods November-December 2013 68(3):394-406
Autor:
Alépée, N., Bessou-Touya, S., Cotovio, J., de Smedt, A., de Wever, B., Faller, C., Jones, P., Le Varlet, B., Marrec-Fairley, M., Pfannenbecker, U., Tailhardat, M., van Goethem, F., McNamee, P.
Publikováno v:
In Toxicology in Vitro August 2013 27(5):1476-1488
Autor:
Pfannenbecker, U., Bessou-Touya, S., Faller, C., Harbell, J., Jacob, T., Raabe, H., Tailhardat, M., Alépée, N., De Smedt, A., De Wever, B., Jones, P., Kaluzhny, Y., Le Varlet, B., McNamee, P., Marrec-Fairley, M., Van Goethem, F.
Publikováno v:
In Toxicology in Vitro March 2013 27(2):619-626
Autor:
Rao M; Discovery, Product Development and Supply (DPDS), Preclinical Sciences and Translational Safety (PSTS), Predictive Investigative and Translational Toxicology (PITT), Janssen Pharmaceutical Companies of Johnson and Johnson, La Jolla, California 92121, United States., Nassiri V; Open Analytics, Jupiterstraat 20, 2600 Antwerpen, Belgium., Alhambra C; Discovery, Product Development and Supply (DPDS), Preclinical Sciences and Translational Safety (PSTS), Predictive Investigative and Translational Toxicology (PITT), Janssen Pharmaceutical Companies of Johnson and Johnson, La Jolla, California 92121, United States., Snoeys J; Discovery, Product Development and Supply (DPDS), Preclinical Sciences and Translational Safety (PSTS), Predictive Investigative and Translational Toxicology (PITT), Janssen Pharmaceutical Companies of Johnson and Johnson, La Jolla, California 92121, United States., Van Goethem F; Discovery, Product Development and Supply (DPDS), Preclinical Sciences and Translational Safety (PSTS), Predictive Investigative and Translational Toxicology (PITT), Janssen Pharmaceutical Companies of Johnson and Johnson, La Jolla, California 92121, United States., Irrechukwu O; Discovery, Product Development and Supply (DPDS), Preclinical Sciences and Translational Safety (PSTS), Predictive Investigative and Translational Toxicology (PITT), Janssen Pharmaceutical Companies of Johnson and Johnson, La Jolla, California 92121, United States., Aleo MD; TOXinsights LLC, Boiling Springs, Pennsylvania 17007, United States., Geys H; Discovery, Product Development and Supply (DPDS), Preclinical Sciences and Translational Safety (PSTS), Predictive Investigative and Translational Toxicology (PITT), Janssen Pharmaceutical Companies of Johnson and Johnson, La Jolla, California 92121, United States., Mitra K; Discovery, Product Development and Supply (DPDS), Preclinical Sciences and Translational Safety (PSTS), Predictive Investigative and Translational Toxicology (PITT), Janssen Pharmaceutical Companies of Johnson and Johnson, La Jolla, California 92121, United States., Will Y; Discovery, Product Development and Supply (DPDS), Preclinical Sciences and Translational Safety (PSTS), Predictive Investigative and Translational Toxicology (PITT), Janssen Pharmaceutical Companies of Johnson and Johnson, La Jolla, California 92121, United States.
Publikováno v:
Chemical research in toxicology [Chem Res Toxicol] 2023 Jul 17; Vol. 36 (7), pp. 1129-1139. Date of Electronic Publication: 2023 Jun 09.
Autor:
Pognan F; Discovery and Investigative Safety, Novartis Pharma AG, Basel, Switzerland. francois.pognan@novartis.com., Beilmann M; Nonclinical Drug Safety Germany, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany., Boonen HCM; Drug Safety, Dept of Exploratory Toxicology, Lundbeck A/S, Valby, Denmark., Czich A; R&D Preclinical Safety, Sanofi, Frankfurt, Germany., Dear G; In Vitro In Vivo Translation, GlaxoSmithKline David Jack Centre for Research, Ware, UK., Hewitt P; Chemical and Preclinical Safety, Merck Healthcare KGaA, Darmstadt, Germany., Mow T; Safety Pharmacology and Early Toxicology, Novo Nordisk A/S, Maaloev, Denmark., Oinonen T; Preclinical Safety, Orion Corporation, Espoo, Finland., Roth A; Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Steger-Hartmann T; Investigational Toxicology, Bayer AG, Berlin, Germany., Valentin JP; Non-Clinical Safety Evaluation, UCB Biopharma SRL, Braine-l'Alleud, Belgium., Van Goethem F; Predictive, Investigative & Translational Toxicology, Nonclinical Safety, Janssen Research & Development, Beerse, Belgium., Weaver RJ; Innovation Life Cycle Management, Institut de Recherches Internationales Servier, Suresnes, France., Newham P; Clinical Pharmacology and Safety Sciences, AstraZeneca R&D, Cambridge, UK. peter.newham@astrazeneca.com.
Publikováno v:
Nature reviews. Drug discovery [Nat Rev Drug Discov] 2023 Apr; Vol. 22 (4), pp. 317-335. Date of Electronic Publication: 2023 Feb 13.
Autor:
Braak, B. Ter, Wolters, L., Elbertse, K., Beilmann, M., Boonen, H., Doherty, A., Van Goethem, F., Hewitt, P., Hornberg, J., Koch, J., Kusterman, S., Lyon, J., Oinonen, T., Raschke, M., Vicart, A., Zeller, A., Jamalpoor, A., Hendriks, G., Steger-Hartmann, T.
Publikováno v:
In Toxicology Letters September 2023 384 Supplement 1:S198-S199
Autor:
dos Santos Rodrigues, B., Cendoya Garmendia, X., Steemans, M., Gustin, E., Van Goethem, F., Vinken, M.
Publikováno v:
In Toxicology Letters September 2023 384 Supplement 1:S186-S187
Autor:
Van Goethem, F., Adriaens, E., Alépée, N., Straube, F., De Wever, B., Cappadoro, M., Catoire, S., Hansen, E., Wolf, A., Vanparys, P.
Publikováno v:
In Toxicology in Vitro February 2006 20(1):1-17
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.